Literature DB >> 33604752

The comparative impact among different intensive statins and combination therapies with niacin/ezetimibe on carotid intima-media thickness: a systematic review, traditional meta-analysis, and network meta-analysis of randomized controlled trials.

Hongwei Li1,2, Xiaolin Xu3, Liming Lu4, Runlu Sun1,2, Qi Guo1,2, Qian Chen1,2, Junjie Wang1,2, Zhijian He1,2, Yuling Zhang5,6.   

Abstract

PURPOSE: To compare the impact of different statins therapies on the reduction of carotid intima-media thickness (CIMT) may reflect their cardiovascular benefits which is useful in clinical decision.
METHODS: PubMed, EMBASE, Cochrane Library, and Web of Science were searched, and 3539 articles published from 1992 to 2020 were retrieved. CIMT in randomized controlled trials for statins therapies were included for traditional and network meta-analyses analyzed by Stata 16. The quality of included studies was assessed by the Cochrane Collaboration's tool.
RESULTS: Thirty-three randomized controlled trials (n=8762) were eligible for network meta-analysis, of which 18 randomized controlled trials (n=5252) were included for comparison between statins and no statins and 11 randomized controlled trials (n=1338) were included for comparison between high-intensity statins or combination with niacin/ezetimibe and moderate/low-intensity statins in 2 traditional meta-analyses. In the traditional meta-analyses, the statins groups significantly reduce CIMT compared to no statins (standard mean difference=-0.207, 95% confidence interval: -0.291 to -0.123, p<0.001), while high-intensity statins or combination with niacin/ezetimibe performed significant CIMT reduction compared to moderate/low-intensity statins (standard mean difference=-0.287, 95% confidence interval: -0.460 to -0.114, p=0.001). In the network meta-analysis, a relative rank for the ability to reduce CIMT was given as follows: combination therapy with niacin (mean rank: 1.7), high-intensity statins, combination therapy with ezetimibe, and moderate/low-intensity statins.
CONCLUSION: Statins combined with niacin performed a greater CIMT reduction compared to high-intensity statins alone and combination therapies with ezetimibe. The advantage of niacin-combined statins therapies to improve cardiovascular endpoint needs further validation through randomized controlled trials. CLINICAL TRIAL REGISTRATION: PROSPERO, CRD42020175972.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  Carotid intima-media thickness; Ezetimibe; Network meta-analysis; Niacin; Statins

Mesh:

Substances:

Year:  2021        PMID: 33604752     DOI: 10.1007/s00228-021-03113-0

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  27 in total

1.  No evidence to support high-intensity statin in Chinese patients with coronary heart disease.

Authors:  Wen Dai; Xian-sheng Huang; Shui-ping Zhao
Journal:  Int J Cardiol       Date:  2015-11-23       Impact factor: 4.164

2.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah
Journal:  J Am Coll Cardiol       Date:  2018-11-10       Impact factor: 24.094

3.  The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.

Authors:  Shui-Ping Zhao; Bi-Lian Yu; Dao-Quan Peng; Yong Huo
Journal:  Atherosclerosis       Date:  2014-01-08       Impact factor: 5.162

4.  Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.

Authors:  T J Smilde; S van Wissen; H Wollersheim; M D Trip; J J Kastelein; A F Stalenhoef
Journal:  Lancet       Date:  2001-02-24       Impact factor: 79.321

5.  A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin.

Authors:  Dan Ran; Hui-Juan Nie; Yu-Lin Gao; Song-Bai Deng; Jian-Lin Du; Ya-Jie Liu; Xiao-Dong Jing; Qiang She
Journal:  Int J Cardiol       Date:  2017-02-23       Impact factor: 4.164

6.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

7.  Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis.

Authors:  Mi Seon Ji; Myung Ho Jeong; Young Keun Ahn; Sang Hyung Kim; Young Jo Kim; Shung Chull Chae; Taek Jong Hong; In Whan Seong; Jei Keon Chae; Chong Jin Kim; Myeong Chan Cho; Seung-Woon Rha; Jang Ho Bae; Ki Bae Seung; Seung Jung Park
Journal:  Int J Cardiol       Date:  2016-09-28       Impact factor: 4.164

8.  Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.

Authors:  Jerome L Fleg; Mihriye Mete; Barbara V Howard; Jason G Umans; Mary J Roman; Robert E Ratner; Angela Silverman; James M Galloway; Jeffrey A Henderson; Matthew R Weir; Charlton Wilson; Mario Stylianou; Wm James Howard
Journal:  J Am Coll Cardiol       Date:  2008-12-16       Impact factor: 24.094

9.  The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.

Authors:  Paul M Lavigne; Richard H Karas
Journal:  J Am Coll Cardiol       Date:  2012-12-19       Impact factor: 24.094

10.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Authors:  François Mach; Colin Baigent; Alberico L Catapano; Konstantinos C Koskinas; Manuela Casula; Lina Badimon; M John Chapman; Guy G De Backer; Victoria Delgado; Brian A Ference; Ian M Graham; Alison Halliday; Ulf Landmesser; Borislava Mihaylova; Terje R Pedersen; Gabriele Riccardi; Dimitrios J Richter; Marc S Sabatine; Marja-Riitta Taskinen; Lale Tokgozoglu; Olov Wiklund
Journal:  Eur Heart J       Date:  2020-01-01       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.